Arrowsmith
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arrowsmith - overview
Established
2025
Location
Tsukuba, -, Japan
Primary Industry
Pharmaceuticals
About
Based in Japan, Arrowsmith Inc. d. b. a Arrowsmith focuses on developing innovative software solutions that enhance operational efficiency and data management for various industries, including logistics, manufacturing, and retail.
Arrowsmith Inc. was founded in 2025 in Tsukuba, Japan. The company specializes in advanced software solutions tailored to meet the operational needs of businesses. In June 2026, Arrowsmith raised JPY 1.
05 billion in series A funding from ANRI, DBJ Capital, JIC Venture Growth Investments and JAFCO Group. Arrowsmith Inc. specializes in innovative software solutions aimed at improving operational efficiency and data management across diverse industries. Their core offerings include advanced software designed to streamline processes and enhance data accuracy, serving clients from large enterprises to small and medium-sized businesses primarily in Asia and North America.
The solutions focus on user-friendly interfaces and robust functionality to aid end users in optimizing workflows and decision-making. Arrowsmith Inc. operates on a revenue model combining subscription services with direct sales to clients. The company offers tailored software packages that align with specific operational needs, allowing clients to subscribe to ongoing services that include support and updates.
They cater to various scales of operations, ensuring flexibility for individual businesses and larger corporate clients, with key products forming the backbone of steady cash flow through recurring subscriptions and long-term partnerships. In June 2026, Arrowsmith raised JPY 1. 05 billion in series A funding from ANRI, DBJ Capital, JIC Venture Growth Investments and JAFCO Group. The company plans to use June 2026 funds to advance clinical trials of ARW001 and support research and development of its subsequent pipeline candidates.
Current Investors
JAFCO Group, JIC Venture Growth Investments, ANRI
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
https://arrowsmith.co.jp
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.